Plain-English translation of NCT06812104 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called KK2845 for people with acute myeloid leukemia or other blood cancers that have come back or stopped responding to standard treatments. The study will start with smaller doses and gradually increase them to find the safest and most effective dose of the medication. This is the very first time KK2845 is being tested in humans.
Many people with relapsed or refractory blood cancers run out of standard treatment options that work. This medication is being studied to see if it can help patients whose cancer has returned or no longer responds to existing therapies.
You likely qualify if…
You likely don't qualify if…
You will receive the medication by injection or infusion at a clinic, starting at a low dose. The dose will gradually increase in groups of patients to find the right level. You will have regular blood tests, heart monitoring, and clinic visits to check how you are tolerating the treatment and how your cancer is responding. The study has two parts: an initial phase to find the safest dose, followed by a phase where additional patients receive that confirmed dose to gather more information about how well it works.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
Japan